A Fixed Dose Combination Amlodipine + Enalapril Bioavailability Study

Model scores of the 29,894 trials active now.

Model score 2% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 7% of the time (318 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-05-24. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: subjectof studydaysusetime
  Phrases that lowered it: healthyamlodipinelabeltabletsingle dose
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Design: crossover (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 4.9% (lowers risk) · Sponsor's track record
• Sponsor's past trials: 1747 (raises risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 335 (raises risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Blinding: none (lowers risk) · Design
• Drug's FAERS reports with a death: 11.4% (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 18369 (lowers risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 102680 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine and Losartan in Health Volunteers NCT01648231 · started 2012 · scored riskier than 1% of active trials completed
• Relative Bioavailability Study of One Amlodipine 10mg Tablet and One Rosuvastatin 20mg Tablet to Two Fixed Dose Combinations of Amlodipine (10mg) and Rosuvastatin (20mg) in Healthy Subjects Under Fasting Conditions NCT02075619 · started 2014 · scored riskier than 0% of active trials completed
• Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 Under Fasting Conditions NCT01797926 · started 2013 · scored riskier than 1% of active trials completed
• A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers NCT02202187 · started 2011 · scored riskier than 5% of active trials completed
• Drug Interaction Study to Investigate Co-administration of GW642444M With Ketoconazole NCT00866515 · started 2008 · scored riskier than 2% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.